Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Equity (2020 - 2025)

Historic Return on Equity for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to 0.58%.

  • Nurix Therapeutics' Return on Equity fell 1500.0% to 0.58% in Q4 2025 from the same period last year, while for Nov 2025 it was 0.58%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.5% for FY2025, which is 400.0% up from last year.
  • Per Nurix Therapeutics' latest filing, its Return on Equity stood at 0.58% for Q4 2025, which was down 1500.0% from 0.6% recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Return on Equity registered a high of 0.2% during Q1 2021, and its lowest value of 0.78% during Q1 2024.
  • Over the past 5 years, Nurix Therapeutics' median Return on Equity value was 0.55% (recorded in 2022), while the average stood at 0.5%.
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -3100bps in 2022, then soared by 3700bps in 2025.
  • Over the past 5 years, Nurix Therapeutics' Return on Equity (Quarter) stood at 0.33% in 2021, then plummeted by -71bps to 0.56% in 2022, then decreased by -19bps to 0.66% in 2023, then surged by 35bps to 0.43% in 2024, then crashed by -36bps to 0.58% in 2025.
  • Its Return on Equity stands at 0.58% for Q4 2025, versus 0.6% for Q3 2025 and 0.45% for Q2 2025.